暗盘资金流向曝光！提前捕捉庄家建仓信号>> 创新药板块短线拉升，海南海药（000566）、哈三联（002900）、华森制药（002907）涨停，睿智医药 （300149）、诺思兰德涨超10%，舒泰神（300204）、海创药业、三元基因、梓橦宫、热景生物等跟 涨。 ...

Group 1 - The core point of the article is the significant stock price increases of several pharmaceutical companies following the approval of 11 innovative drugs by the National Medical Products Administration on May 29 [1] Group 2 - Harbin Pharmaceutical Group (哈三联) reached the daily limit increase in stock price [1] - Companies such as Ruizhi Pharmaceutical (睿智医药), Xinnowei (新诺威), Hainan Haiyao (海南海药), and Huasen Pharmaceutical (华森制药) saw stock price increases of over 5% [1] - Other companies including Fosun Pharma (复星医药), Yipinhong (一品红), Haiwang Biological (海王生物), and Northeast Pharmaceutical (东北制药) also experienced stock price increases [1]

Group 1 - The innovative drug sector in A-shares has shown a strong comeback, with multiple stocks experiencing significant price increases, including Shuyou Shen (20% increase) and Ruizhi Pharmaceutical (20% increase), indicating a bullish market sentiment [1] - The Hong Kong market also saw a rise, with WuXi AppTec increasing by 19.88% and several innovative drug ETFs in Hong Kong showing year-to-date gains exceeding 40%, outperforming similar products [1][2] - Analysts suggest that the domestic market is entering a concentrated listing period for innovative drugs, supported by comprehensive policy backing and improvements in commercial medical insurance, which are expected to enhance the commercialization process beyond market expectations [1][5] Group 2 - There is a noticeable divergence in the performance of various medical ETFs, with some experiencing significant inflows while others face substantial outflows, indicating mixed investor sentiment [2][3] - The top-performing innovative drug ETFs, such as ICBC Hong Kong Innovative Drug ETF and Huatai-PineBridge Hong Kong Innovative Drug ETF, have seen net inflows of 2.43 billion and 2.31 billion respectively, while the E Fund CSI 300 Healthcare ETF has recorded the highest net outflow of 2.5 billion [3] - The medical sector is expected to show its best performance in three years by mid-2025, driven by policy optimization and AI industry empowerment, with a clear trend of performance and valuation recovery anticipated in the second half of the year [3] Group 3 - The innovative drug sector has rebounded significantly after a period of decline, with innovative drug ETFs showing substantial weekly gains, particularly in the lead-up to the ASCO annual meeting, which has heightened industry interest [4] - The upcoming ASCO meeting is expected to showcase numerous original research results from Chinese pharmaceutical companies, indicating a shift towards international innovation in drug development [4][5] - Recent approvals of six domestic innovative drugs in May across critical treatment areas such as diabetes and tumors have injected strong momentum into the pharmaceutical industry [5]

证券代码：002907 证券简称：华森制药 公告编号：2025-049 本次公司重点产品痛泻宁颗粒获得新加坡注册批文，是公司继甘桔冰梅片、 六味安神胶囊、都梁软胶囊后第四个成功实现海外注册的产品。此举标志着公司 产品在国际市场的认可度再次提升，这不仅增强了公司在全球医药行业的竞争力， 也为公司带来了更广阔的发展空间和市场机遇，进而推动公司整体国际化战略的 深入实施。此外，痛泻宁颗粒的成功注册，也将促进公司在研发和创新方面持续 投入，公司将不断提升产品质量和技术水平，为全球患者提供更多优质、有效的 医药产品。 | 产 | 品 | 名 | 称 ：TONGXIENING KELI （痛泻宁颗粒） | | --- | --- | --- | --- | | 产 | 品 | 类 | 别 ：中成药 | | 品 | 牌 | 名 | 称 ：华森 | | 剂 | | | 型 ：颗粒剂（内服） | | 生 | 产 | | 商 ：重庆华森制药股份有限公司 | | 注 | 册 | 编 | 号 ：129808 | 二、药品的其他情况 痛泻宁颗粒源于经典名方（"痛泻要方"），为全球首个治疗 IBS-D 的天然 植物药。该药物具有"疏肝理 ...

Market Overview - The three major A-share indices rose collectively in the morning session, with the Shanghai Composite Index up 0.72%, the Shenzhen Component Index up 1.12%, and the ChiNext Index up 1.16% [1] - The total market turnover reached 759.4 billion yuan, an increase of 91.6 billion yuan compared to the previous day, with over 4,400 stocks rising [1] Sector Performance - The leading sectors included autonomous driving, innovative pharmaceuticals, and cross-border payments, while precious metals and food sectors saw declines [2] - Notable stocks in the autonomous driving sector included Yunnei Power and Tongda Electric, both achieving four consecutive trading limit increases [2] - The innovative pharmaceutical sector also performed well, with stocks like Ruizhi Pharmaceutical and Shutaishen hitting trading limits [2] Notable Stocks and Trends - The stock of Shangwei Co. achieved six consecutive trading limit increases, indicating strong investor interest [4] - Stocks such as Yunnei Power and Tongda Electric have shown significant momentum with four consecutive trading limit increases [5] - The innovative pharmaceutical company Shutaishen reported promising clinical trial results for its STSA-1002 injection, showing a significant reduction in mortality rates compared to the control group [10] Strategic Developments - A strategic cooperation framework agreement was signed between Xiaoma Zhixing and Guangzhou Public Transport Group to collaborate in the fields of autonomous vehicles and logistics services [11] - The market is also reacting to legislative developments regarding stablecoins in the U.S. and Hong Kong, which may impact the cross-border payment sector [13]

公司同时提示，本次STSA-1002注射液（急性呼吸窘迫综合征适应症）仅取得顶线数据的初步统计分析 结果，STSA-1002注射液项目在该适应症方向的完整有效性、安全性结果将以未来最终临床总结报告为 准。本次STSA-1002注射液（急性呼吸窘迫综合征适应症）获得Ib/II期临床试验研究初步结果不会对公 司当前业绩产生重大影响。后续临床试验阶段是否顺利、能否获得生产批件、具备上市资格尚存在诸多 不确定。 创新药概念29日盘中强势拉升，截至发稿，睿智医药（300149）、舒泰神（300204）20%涨停，键凯科 技、益方生物涨超12%，华森制药（002907）涨停斩获3连板，博瑞医药涨超8%。 行业方面，当地时间2025年5月30日至6月3日，2025年美国临床肿瘤学会（ASCO）年会将在美国芝加 哥举行。据悉，ASCO年会作为全球规模最大、学术水平最高、最具权威性的临床肿瘤学会议之一，见 证了中国肿瘤学研究的发展。目前，中国药企入选的临床研究逐年增多，展示了其在新药研发方面的活 跃度和竞争力，2025年中国学者入选会议的研究达到70余项，其中恒瑞医药（600276）、信达生物、荣 昌生物、泽璟制药、正大天晴、 ...

Group 1 - The stock of Huason Pharmaceutical has reached a limit-up, marking three consecutive limit-up days, with a current price of 18.80 yuan and a turnover rate of 8.06% [2] - During the consecutive limit-up period, the stock has increased by 33.05%, with a cumulative turnover rate of 22.87% [2] - The latest total market capitalization of the A-shares is 78.51 billion yuan, with a circulating market capitalization of 58.07 billion yuan [2] Group 2 - The stock has appeared on the Dragon and Tiger List due to a cumulative deviation of 20% in its price over three trading days, with institutional net purchases amounting to 3.3683 million yuan and a total net sale by the Shenzhen Stock Connect of 32.3933 million yuan [2] - The company reported a total operating revenue of 239 million yuan for the first quarter, representing a year-on-year growth of 4.62%, and a net profit of 40 million yuan, with a slight increase of 0.01% year-on-year [2] Group 3 - Recent trading data shows significant fluctuations in daily price changes and net inflows of main funds, with the highest daily increase recorded at 9.97% on May 28, 2025, and a net inflow of 59.923 million yuan [2] - The stock has experienced varying turnover rates, with the highest at 11.94% on the same day, indicating active trading [2]

Group 1 - The stock of Chongqing Huason Pharmaceutical Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative price increase of 21.52% over two consecutive trading days on May 27 and May 28, 2025 [1][2] - The company's board confirmed that there were no undisclosed significant matters that could have impacted the stock price, and the operational situation remains normal without any major changes [1][2] - The controlling shareholder and actual controller did not engage in buying or selling the company's stock during the period of abnormal trading [2] Group 2 - The board of directors confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's regulations [2] - The company emphasized that it has not violated any information disclosure regulations and reminded investors to pay attention to potential risks as outlined in the 2024 annual report [2]

股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况的说明 重庆华森制药股份有限公司（以下简称"公司"）股票（证券简称：华森制 药，证券代码：002907）于 2025 年 5 月 27 日、5 月 28 日连续 2 个交易日内收 盘价涨幅偏离值累计达到 21.52%。根据《深圳证券交易所交易规则》的有关规 定，属于股票交易异常波动情况。 证券代码：002907 证券简称：华森制药 公告编号：2025-048 重庆华森制药股份有限公司 （五）经核查，控股股东、实际控制人在股票异常波动期间不存在买卖公司 股票的情形。 三、是否存在应披露而未披露信息的说明 本公司董事会确认，本公司目前没有任何根据深交所《股票上市规则》等有 关规定应予以披露而未披露的事项或与该事项有关的筹划、商谈、意向、协议等； 董事会也未获悉本公司有根据深交所《股票上市规则》等有关规定应予以披露而 未披露的、对本公司股票及其衍生品种交易价格产生较大影响的信息；公司前期 披露的信息不存在需要更正、补充之处。 四、上市公司认为必要的风险提示 二、对重要问题的 ...

证券代码：002907 证券简称：华森制药 公告编号：2025-047 重庆华森制药股份有限公司 一、《药品再注册批准通知书》主要信息 增生、甲状腺结节、子宫肌瘤等疗效突出，可软化包块、缩小囊肿、减轻症状。 平消片被列入《肿瘤中医诊疗指南》《中医外科常见病诊疗指南》《中成药临床 应用指南·消化疾病分册》《中成药临床应用指南·呼吸系统疾病分册》《临床 路径治疗药物释义肿瘤疾病分册》《中医临床诊疗指南释义》《国家基本药物临 床应用指南(中成药)》等多项临床指南或专家共识。 三、对公司的影响 本次公司获得平消片的《药品再注册批准通知书》将确保该药品的正常生产 和销售，公司将严格按照要求开展相关工作，控制产品质量，持续为市场提供 高品质的产品。 关于公司收到药品再注册批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重庆华森制药股份有限公司（以下简称"公司"）于近日收到重庆市药品监 督管理局（以下简称"市药监局"）核准签发的关于公司药品平消片的《药品再 注册批准通知书》。现将相关情况公告如下： | 药 | 品 | | 通 | 用 | | 名 称：平消片 ...